Your browser doesn't support javascript.
loading
Novel ligands for P2 receptor subtypes in innervated tissues.
Lambrecht, G; Damer, S; Niebel, B; Czeche, S; Nickel, P; Rettinger, J; Schmalzing, G; Mutschler, E.
Affiliation
  • Lambrecht G; Department of Pharmacology, Biocentre Niederursel, University of Frankfurt, Main, Germany. lambrecht@em.uni-frankfurt.de
Prog Brain Res ; 120: 107-17, 1999.
Article in En | MEDLINE | ID: mdl-10550991
ABSTRACT
Among suramin analogues, the properties of P2 receptor subtype blockade and ecto-nucleotidase inhibition appear to be controlled by different structural parameters (Fig. 1 and 2, Table 1; Van Rhee et al., 1994; Beukers et al., 1995; Bültmann et al., 1996; Damer et al., 1998a, 1998b; and this study) the molecular size of the compounds, the position of the sulfonic acid residues in the naphthalene rings, the substitution pattern of the benzoyl moieties and the 3'- or 4'-aminobenzoyl-linkages of the phenyl rings "1" and "2". As a result, compounds with different receptor selectivity profiles were obtained. A maximum in potency at and selectivity for P2X1 receptors is reached in NF279, which is a specific P2 receptor antagonist and the compound with the highest P2X1 vs. P2Y receptor and ecto-nucleotidase selectivity presently available.
Subject(s)
Search on Google
Collection: 01-internacional Database: MEDLINE Main subject: Suramin / Adenosine Triphosphate / Receptors, Purinergic P2 Limits: Animals Language: En Journal: Prog Brain Res Year: 1999 Document type: Article
Search on Google
Collection: 01-internacional Database: MEDLINE Main subject: Suramin / Adenosine Triphosphate / Receptors, Purinergic P2 Limits: Animals Language: En Journal: Prog Brain Res Year: 1999 Document type: Article